| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Laurie L Baggio, Daniel J Drucke. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best practice & research. Clinical endocrinology & metabolism. vol 18. issue 4. 2005-04-08. PMID:15533774. |
glp-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. |
2005-04-08 |
2023-08-12 |
Not clear |
| Izumi Takei, Tomohiro Kasatan. Future therapy of diabetes mellitus. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 58. issue 10. 2005-04-08. PMID:15589066. |
glucagon-like peptide 1(glp-1) analogs and alternative routes of insulin, especially oral (enteric-gastrointestinal, inhaled) route, are most promising and attractive now. |
2005-04-08 |
2023-08-12 |
Not clear |
| Bo Ahrén, Thomas E Hughe. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. vol 146. issue 4. 2005-04-08. PMID:15604213. |
in this study, we explored whether dpp-4 inhibition by valine-pyrrolidide (val-pyr; 100 micromol/kg administered through gastric gavage at t = -30 min) affects the insulin and glucose responses to iv glucose (1 g/kg) together with glp-1 (10 nmol/kg), glucose-dependent insulinotropic polypeptide (gip; 10 nmol/kg), pituitary adenylate cyclase-activating polypeptide 38 (pacap38; 1.3 nmol/kg), or gastrin-releasing peptide (grp; 20 nmol/kg) given at t = 0 in anesthetized c57bl/6j mice. |
2005-04-08 |
2023-08-12 |
mouse |
| Bo Ahrén, Thomas E Hughe. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. vol 146. issue 4. 2005-04-08. PMID:15604213. |
it was found that the acute (1-5 min) insulin response to glp-1 was augmented by val-pyr by 80% (4.2 +/- 0.4 vs. 7.6 +/- 0.8 nmol/liter), that to gip by 40% (2.7 +/- 0.3 vs. 3.8 +/- 0.4 nmol/liter), that to pacap38 by 75% (4.6 +/- 0.5 vs. 8.1 +/- 0.6 nmol/liter), and that to grp by 25% (1.8 +/- 0.2 vs. 2.3 +/- 0.3 nmol/liter; all p < 0.05 or less). |
2005-04-08 |
2023-08-12 |
mouse |
| Bo Ahrén, Thomas E Hughe. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. vol 146. issue 4. 2005-04-08. PMID:15604213. |
the augmented insulin response to grp by val-pyr was prevented by the glp-1 receptor antagonist, exendin(3) (9-39), raising the possibility that grp effects may occur secondary to stimulation of glp-1 secretion. |
2005-04-08 |
2023-08-12 |
mouse |
| Bo Ahrén, Thomas E Hughe. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. vol 146. issue 4. 2005-04-08. PMID:15604213. |
we conclude that dpp-4 inhibition augments the insulin response not only to glp-1 but also to gip, pacap38, and grp. |
2005-04-08 |
2023-08-12 |
mouse |
| Laurie L Baggio, Daniel J Drucke. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treatments in endocrinology. vol 1. issue 2. 2005-04-06. PMID:15765627. |
glp-1 administration stimulates glucose-dependent insulin secretion, inhibits glucagon secretion, and lowers blood glucose in normal and diabetic rodents and in humans. |
2005-04-06 |
2023-08-12 |
Not clear |
| Koichi Sugita, Saori Endo-Kasahara, Yoshifumi Tada, Yang Lijun, Hiroshi Yasuda, Yuji Hayashi, Takahito Jomori, Hiroyasu Ebinuma, Fumio Takaiw. Genetically modified rice seeds accumulating GLP-1 analogue stimulate insulin secretion from a mouse pancreatic beta-cell line. FEBS letters. vol 579. issue 5. 2005-04-05. PMID:15710395. |
genetically modified rice seeds accumulating glp-1 analogue stimulate insulin secretion from a mouse pancreatic beta-cell line. |
2005-04-05 |
2023-08-12 |
mouse |
| Koichi Sugita, Saori Endo-Kasahara, Yoshifumi Tada, Yang Lijun, Hiroshi Yasuda, Yuji Hayashi, Takahito Jomori, Hiroyasu Ebinuma, Fumio Takaiw. Genetically modified rice seeds accumulating GLP-1 analogue stimulate insulin secretion from a mouse pancreatic beta-cell line. FEBS letters. vol 579. issue 5. 2005-04-05. PMID:15710395. |
we found that glp-1 analogue derived from trypsin-digested genetically modified rice seeds stimulated insulin secretion from a mouse pancreatic beta-cell line, min6. |
2005-04-05 |
2023-08-12 |
mouse |
| Bo Ahré. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease]. Lakartidningen. vol 102. issue 8. 2005-03-30. PMID:15786905. |
glp-1 is released from the gut during a meal intake and stimulates insulin secretion. |
2005-03-30 |
2023-08-12 |
human |
| Nobuyuki Yasuda, Takashi Inoue, Tadashi Nagakura, Kazuto Yamazaki, Kazunobu Kira, Takao Saeki, Isao Tanak. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. The Journal of pharmacology and experimental therapeutics. vol 310. issue 2. 2005-03-28. PMID:15039452. |
an incretin hormone, glucagon-like peptide-1 (glp-1), has been shown to lower plasma glucose via glucose-dependent insulin secretion and to reduce appetite. |
2005-03-28 |
2023-08-12 |
rat |
| Nobuyuki Yasuda, Takashi Inoue, Tadashi Nagakura, Kazuto Yamazaki, Kazunobu Kira, Takao Saeki, Isao Tanak. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. The Journal of pharmacology and experimental therapeutics. vol 310. issue 2. 2005-03-28. PMID:15039452. |
in an oral glucose tolerance test on day 1, the coadministration caused a greater improvement of glucose tolerance and a prominent increase of plasma active glp-1 without marked insulin secretion. |
2005-03-28 |
2023-08-12 |
rat |
| Akira Hirasawa, Keiko Tsumaya, Takeo Awaji, Susumu Katsuma, Tetsuya Adachi, Masateru Yamada, Yukihiko Sugimoto, Shunichi Miyazaki, Gozoh Tsujimot. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature medicine. vol 11. issue 1. 2005-03-24. PMID:15619630. |
gut polypeptides secreted in response to food intake, such as glucagon-like peptide-1 (glp-1), are potent incretin hormones that enhance the glucose-dependent secretion of insulin from pancreatic beta cells. |
2005-03-24 |
2023-08-12 |
Not clear |
| Akira Hirasawa, Keiko Tsumaya, Takeo Awaji, Susumu Katsuma, Tetsuya Adachi, Masateru Yamada, Yukihiko Sugimoto, Shunichi Miyazaki, Gozoh Tsujimot. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature medicine. vol 11. issue 1. 2005-03-24. PMID:15619630. |
furthermore, we show that the stimulation of gpr120 by ffas promotes the secretion of glp-1 in vitro and in vivo, and increases circulating insulin. |
2005-03-24 |
2023-08-12 |
Not clear |
| Jesper Gromada, Birgitte Brock, Ole Schmitz, Patrik Rorsma. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic & clinical pharmacology & toxicology. vol 95. issue 6. 2005-03-18. PMID:15569269. |
the stimulatory action of glp-1 on insulin secretion involves interaction with a plethora of signal transduction processes including ion channel activity, intracellular ca(2+) handling and exocytosis of the insulin-containing granules. |
2005-03-18 |
2023-08-12 |
Not clear |
| Jesper Gromada, Birgitte Brock, Ole Schmitz, Patrik Rorsma. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic & clinical pharmacology & toxicology. vol 95. issue 6. 2005-03-18. PMID:15569269. |
in this review we focus principally on recent advances in our understanding on the cellular mechanisms proposed to underlie glp-1's insulinotropic effect and attempt to incorporate this knowledge into a working model for the control of insulin secretion. |
2005-03-18 |
2023-08-12 |
Not clear |
| B D Green, V A Gault, M H Mooney, N Irwin, C J Bailey, P Harriott, B Greer, P R Flatt, F P M O'Hart. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. Journal of molecular endocrinology. vol 31. issue 3. 2005-03-17. PMID:14664713. |
although the incretin hormone glucagon-like peptide-1 (glp-1) is a potent stimulator of insulin release, its rapid degradation in vivo by the enzyme dipeptidyl peptidase iv (dpp iv) greatly limits its potential for treatment of type 2 diabetes. |
2005-03-17 |
2023-08-12 |
mouse |
| B D Green, V A Gault, M H Mooney, N Irwin, C J Bailey, P Harriott, B Greer, P R Flatt, F P M O'Hart. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. Journal of molecular endocrinology. vol 31. issue 3. 2005-03-17. PMID:14664713. |
consistent with other mechanisms of action, the analogues showed similar, or in the case of (val(8))glp-1 slightly impaired insulin releasing activity in brin bd11 cells. |
2005-03-17 |
2023-08-12 |
mouse |
| E M Egido, R A Silvestre, R Hernández, J Marc. Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 9. 2005-03-03. PMID:15486809. |
we have investigated the effect of exendin-4, a glp-1 analogue, on somatostatin and insulin secretion in perfused rat pancreas. |
2005-03-03 |
2023-08-12 |
rat |
| Brian Furman, Nigel Pyne, Peter Flatt, Finbarr O'Hart. Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. The Journal of pharmacy and pharmacology. vol 56. issue 12. 2005-03-01. PMID:15563754. |
cyclic 3'5'amp is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet beta-cell, where it is formed by the activity of adenylyl cyclase, especially in response to the incretin hormones glp-1 (glucagon-like peptide-1) and gip (glucose-dependent insulinotropic peptide). |
2005-03-01 |
2023-08-12 |
Not clear |